Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising?

Author(s): Ritika Rana, Ruchika Sharma, Anoop Kumar*.

Journal Name: Infectious Disorders - Drug Targets
(Formerly Current Drug Targets - Infectious Disorders)

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Today’s microbial infections’ resistance to approved drugs, the emergence of new infectious diseases and lack of vaccines, create a huge threat to human health. Thus, there is an urgent need to create novel antimicrobial agents, but the high cost and prolonged timeline of novel drug discovery and development is the major barrier to make new drugs. Therefore, there is a need for specific cost effective approaches in order to identify new drugs for the treatment of various microbial infections. Drug repurposition is an alternative technique to find existing clinically approved drugs for other indications. This approach may enhance the portfolio of Pharmaceutical companies by reducing the time and money required for the development of new chemical entity. In literature, various studies have reported some encouraging results regarding the antimicrobial use of existing statin drugs. Further, some clinical studies have also shown the protective effect of statin drugs in reduction of the morbidity and mortality due to many infectious diseases but complete understanding is still lacking. Thus, there is a need for better understanding of the use of statin drugs, especially in the context of antimicrobial effects. In this review, we try to summarize the use of statin drugs in various infectious diseases and their proposed antimicrobial mechanism of action. Further, current challenges and future perspectives of repurposition of statin drugs as antimicrobial agents have also been discussed.

Keywords: Drug-resistance, drug repurposition, statin drugs, antimicrobial activity, microbial infections, treatment.

[1]
Cohen, M.L. Changing patterns of infectious disease. Nature, 2000, 406(6797), 762-767.
[http://dx.doi.org/10.1038/35021206] [PMID: 10963605]
[2]
Wolfe, N.D.; Dunavan, C.P.; Diamond, J. Origins of major human infectious diseases. Nature, 2007, 447(7142), 279-283.
[http://dx.doi.org/10.1038/nature05775] [PMID: 17507975]
[3]
Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, 39(3), 309-317.
[http://dx.doi.org/10.1086/421946] [PMID: 15306996]
[4]
Khalifah, A.P.; Hachem, R.R.; Chakinala, M.M.; Schechtman, K.B.; Patterson, G.A.; Schuster, D.P.; Mohanakumar, T.; Trulock, E.P.; Walter, M.J. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am. J. Respir. Crit. Care Med., 2004, 170(2), 181-187.
[http://dx.doi.org/10.1164/rccm.200310-1359OC] [PMID: 15130908]
[5]
Datta, R.; Huang, S.S. Risk of infection and death due to methicillin-resistant Staphylococcus aureus in long-term carriers. Clin. Infect. Dis., 2008, 47(2), 176-181.
[http://dx.doi.org/10.1086/589241] [PMID: 18532892]
[6]
Nigam, A.; Gupta, D.; Sharma, A. Treatment of infectious disease: beyond antibiotics. Microbiol. Res., 2014, 169(9-10), 643-651.
[http://dx.doi.org/10.1016/j.micres.2014.02.009] [PMID: 24661689]
[7]
Clinical Trial Registry of India. http://ctri.nic.in/Clinicaltrials/login.php
[8]
Ventola, C.L. The antibiotic resistance crisis: part 1: causes and threats. P&T, 2015, 40(4), 277-283.
[PMID: 25859123]
[9]
Rossolini, G.M.; Arena, F.; Pecile, P.; Pollini, S. Update on the antibiotic resistance crisis. Curr. Opin. Pharmacol., 2014, 18, 56-60.
[http://dx.doi.org/10.1016/j.coph.2014.09.006] [PMID: 25254623]
[10]
Davies, J.; Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev., 2010, 74(3), 417-433.
[http://dx.doi.org/10.1128/MMBR.00016-10] [PMID: 20805405]
[11]
Kumar, A. Ebola virus altered innate and adaptive immune response signalling pathways: Implications for novel therapeutic approaches. Infect. Disord. Drug Targets, 2016, 16(2), 79-94.
[http://dx.doi.org/10.2174/1871526516666160108114644] [PMID: 26743519]
[12]
Jadav, S.S.; Ganta, N.M.; Kumar, A.; Dan, N.; Mohanty, N.P. The updates on Middle East Respiratory Syndrome coronavirus (MERS-CoV) epidemiology, pathogenesis, viral genome and currently available drugs. J Pharma Chem., 2016, 3(2), 10-18.
[http://dx.doi.org/10.14805/jphchem.2016.art47]
[13]
Paul, AC.; Brantner, VV. Spending on new drug development., 2010.
[14]
Morgan, S.; Grootendorst, P.; Lexchin, J.; Cunningham, C.; Greyson, D. The cost of drug development: a systematic review. Health Policy, 2011, 100(1), 4-17.
[http://dx.doi.org/10.1016/j.healthpol.2010.12.002] [PMID: 21256615]
[15]
Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3(8), 673-683.
[http://dx.doi.org/10.1038/nrd1468] [PMID: 15286734]
[16]
Kauppi, D.M. Therapeutic Drug Repurposing, Repositioning and Rescue; Drug Discov, 2015, p. 16.
[17]
Galiè, N.; Ghofrani, H.A.; Torbicki, A.; Barst, R.J.; Rubin, L.J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A.; Grimminger, F.; Kurzyna, M.; Simonneau, G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med., 2005, 353(20), 2148-2157.
[http://dx.doi.org/10.1056/NEJMoa050010] [PMID: 16291984]
[18]
Goldstein, I.; Lue, T.F.; Padma-Nathan, H.; Rosen, R.C.; Steers, W.D.; Wicker, P.A. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med., 1998, 338(20), 1397-1404.
[http://dx.doi.org/10.1056/NEJM199805143382001] [PMID: 9580646]
[19]
Fernandes, P. Antibacterial discovery and development--the failure of success? Nat. Biotechnol., 2006, 24(12), 1497-1503.
[http://dx.doi.org/10.1038/nbt1206-1497] [PMID: 17160049]
[20]
Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292(5519), 1160-1164.
[http://dx.doi.org/10.1126/science.1059344] [PMID: 11349148]
[21]
Maron, D.J.; Fazio, S.; Linton, M.F. Current perspectives on statins. Circulation, 2000, 101(2), 207-213.
[http://dx.doi.org/10.1161/01.CIR.101.2.207] [PMID: 10637210]
[22]
Zhou, Q.; Liao, J.K. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ. J., 2010, 74(5), 818-826.
[http://dx.doi.org/10.1253/circj.CJ-10-0110] [PMID: 20424337]
[23]
Jain, M.K.; Ridker, P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov., 2005, 4(12), 977-987.
[http://dx.doi.org/10.1038/nrd1901] [PMID: 16341063]
[24]
Tristano, A.G.; Fuller, K. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int. Immunopharmacol., 2006, 6(12), 1833-1846.
[http://dx.doi.org/10.1016/j.intimp.2006.08.006] [PMID: 17052674]
[25]
Jerwood, S.; Cohen, J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother., 2008, 61(2), 362-364.
[http://dx.doi.org/10.1093/jac/dkm496] [PMID: 18086693]
[26]
Morens, D.M.; Folkers, G.K.; Fauci, A.S. The challenge of emerging and re-emerging infectious diseases. Nature, 2004, 430(6996), 242-249.
[http://dx.doi.org/10.1038/nature02759] [PMID: 15241422]
[27]
Datta, R.; Huang, S.S. Risk of infection and death due to methicillin-resistant Staphylococcus aureus in long-term carriers. Clin. Infect. Dis., 2008, 47(2), 176-181.
[http://dx.doi.org/10.1086/589241] [PMID: 18532892]
[28]
Kumar, A.; Sasmal, D.; Sharma, N. Understanding of complex signaling pathways of immune system: a review. World J. Pharm. Pharm. Sci., 2014, 3, 241-255.
[29]
Kumar, A.; Sharma, N.; Singh, S.; Sasmal, D.; Dev, A. Oral vaccine antigen induced immune response signalling pathways: current and future perspectives. J. Vaccines Vaccin., 2014, 5, 2-6.
[30]
Osborn, O.; Olefsky, J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med., 2012, 18(3), 363-374.
[http://dx.doi.org/10.1038/nm.2627] [PMID: 22395709]
[31]
Poulain, B.; Stiles, BG.; Popoff, MR.; Molgó, J. Attack of the nervous system by clostridial toxins: Physical findings, cellular and molecular actions. The Sourcebook of Bacterial Protein Toxins, , 2006, 348-389.
[32]
Schmitt, C.K.; Meysick, K.C.; O’Brien, A.D. Bacterial toxins: friends or foes? Emerg. Infect. Dis., 1999, 5(2), 224-234.
[http://dx.doi.org/10.3201/eid0502.990206] [PMID: 10221874]
[33]
Eichner, M.; Dietz, K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am. J. Epidemiol., 1996, 143(8), 816-822.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a008820] [PMID: 8610692]
[34]
Richardson, E.T.; Barrie, M.B.; Nutt, C.T.; Kelly, J.D.; Frankfurter, R.; Fallah, M.P.; Farmer, P.E. The Ebola suspect’s dilemma. Lancet Glob. Health, 2017, 5(3), e254-e256.
[http://dx.doi.org/10.1016/S2214-109X(17)30041-4] [PMID: 28193386]
[35]
Jadav, S.S.; Kumar, A.; Ahsan, M.J.; Jayaprakash, V. Ebola virus: current and future perspectives. Infect. Disord. Drug Targets, 2015, 15(1), 20-31.
[http://dx.doi.org/10.2174/1871526515666150320162259] [PMID: 25910510]
[36]
Fatahzadeh, M.; Schwartz, R.A. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol., 2007, 57(5), 737-763.
[http://dx.doi.org/10.1016/j.jaad.2007.06.027] [PMID: 17939933]
[37]
Fernandes, J.A.; Prandini, T.H.; Castro, M.D.; Arantes, T.D.; Giacobino, J.; Bagagli, E.; Theodoro, R.C. Evolution and Application of Inteins in Candida species: A Review. Front. Microbiol., 2016, 7, 1585-1590.
[http://dx.doi.org/10.3389/fmicb.2016.01585] [PMID: 27777569]
[38]
Crunkhorn, S. Fungal infection: Protecting from Candida albicans. Nat. Rev. Drug Discov., 2016, 15(9), 604-604.
[PMID: 27573232]
[39]
Schuetz, A.N. Invasive fungal infections: biomarkers and molecular approaches to diagnosis. Clin. Lab. Med., 2013, 33(3), 505-525.
[http://dx.doi.org/10.1016/j.cll.2013.03.009] [PMID: 23931836]
[40]
Romani, L. Immunity to fungal infections. Nat. Rev. Immunol., 2011, 11(4), 275-288.
[http://dx.doi.org/10.1038/nri2939] [PMID: 21394104]
[41]
Brown, GD.; Denning, DW.; Gow, NA.; Levitz, SM.; Netea, MG.; White, TC. Hidden killers: human fungal infections., 2012.
[http://dx.doi.org/10.1126/scitranslmed.3004404]
[42]
Mah, TFC.; O'Toole, GA. Mechanisms of biofilm resistance to antimicrobial agents.,
[http://dx.doi.org/10.1016/S0966-842X(00)01913-2]
[43]
Rippon, J.W. Medical mycology; the pathogenic fungi and the pathogenic actinomycetes; WB Saunders Company: Eastbourne, UK, 1982.
[44]
Barnhill, A.E.; Brewer, M.T.; Carlson, S.A. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob. Agents Chemother., 2012, 56(8), 4046-4051.
[http://dx.doi.org/10.1128/AAC.00678-12] [PMID: 22615289]
[45]
Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr Computational methods in drug discovery. Pharmacol. Rev., 2013, 66(1), 334-395.
[http://dx.doi.org/10.1124/pr.112.007336] [PMID: 24381236]
[46]
Corsello, S.M.; Bittker, J.A.; Liu, Z.; Gould, J.; McCarren, P.; Hirschman, J.E.; Johnston, S.E.; Vrcic, A.; Wong, B.; Khan, M.; Asiedu, J.; Narayan, R.; Mader, C.C.; Subramanian, A.; Golub, T.R. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med., 2017, 23(4), 405-408.
[http://dx.doi.org/10.1038/nm.4306] [PMID: 28388612]
[47]
Padhy, B.M.; Gupta, Y.K. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J. Postgrad. Med., 2011, 57(2), 153-160.
[http://dx.doi.org/10.4103/0022-3859.81870] [PMID: 21654146]
[48]
Sanseau, P.; Jacob, K. Computational methods for drug repurposing; Brief Bioinf, 2011, pp. 301-302.
[49]
Jin, G.; Wong, S.T. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today, 2014, 19(5), 637-644.
[http://dx.doi.org/10.1016/j.drudis.2013.11.005] [PMID: 24239728]
[50]
Jacob, K.S.; Ganguly, S.; Kumar, P.; Poddar, R.; Kumar, A. Homology model, molecular dynamics simulation and novel pyrazole analogs design of Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy. J. Biomol. Struct. Dyn., 2017, 35(7), 1446-1463.
[http://dx.doi.org/10.1080/07391102.2016.1185380] [PMID: 27142238]
[51]
Hurle, M.R.; Yang, L.; Xie, Q.; Rajpal, D.K.; Sanseau, P.; Agarwal, P. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Ther., 2013, 93(4), 335-341.
[http://dx.doi.org/10.1038/clpt.2013.1] [PMID: 23443757]
[52]
Andronis, C.; Sharma, A.; Virvilis, V.; Deftereos, S.; Persidis, A. Literature mining, ontologies and information visualization for drug repurposing. Brief. Bioinform., 2011, 12(4), 357-368.
[http://dx.doi.org/10.1093/bib/bbr005] [PMID: 21712342]
[53]
Pacini, C.; Iorio, F.; Gonçalves, E.; Iskar, M.; Klabunde, T.; Bork, P.; Saez-Rodriguez, J. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics, 2013, 29(1), 132-134.
[http://dx.doi.org/10.1093/bioinformatics/bts656] [PMID: 23129297]
[54]
Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3(8), 673-683.
[http://dx.doi.org/10.1038/nrd1468] [PMID: 15286734]
[55]
Endo, A. A historical perspective on the discovery of statins. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci., 2010, 86(5), 484-493.
[http://dx.doi.org/10.2183/pjab.86.484] [PMID: 20467214]
[56]
Stancu, C.; Sima, A. Statins: mechanism of action and effects. J. Cell. Mol. Med., 2001, 5(4), 378-387.
[http://dx.doi.org/10.1111/j.1582-4934.2001.tb00172.x] [PMID: 12067471]
[57]
Masadeh, M.; Mhaidat, N.; Alzoubi, K.; Al-Azzam, S.; Alnasser, Z. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann. Clin. Microbiol. Antimicrob., 2012, 11(1), 13-18.
[http://dx.doi.org/10.1186/1476-0711-11-13] [PMID: 22564676]
[58]
Goldstein, M.R.; Mascitelli, L.; Pezzetta, F. Methicillin-resistant Staphylococcus aureus: a link to statin therapy? Cleve. Clin. J. Med., 2008, 75(5), 328-329.
[http://dx.doi.org/10.3949/ccjm.75.5.328-b] [PMID: 18557183]
[59]
Thomsen, R.W.; Hundborg, H.H.; Johnsen, S.P.; Pedersen, L.; Sørensen, H.T.; Schønheyder, H.C.; Lervang, H.H. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit. Care Med., 2006, 34(4), 1080-1086.
[http://dx.doi.org/10.1097/01.CCM.0000207345.92928.E4] [PMID: 16484926]
[60]
Falagas, M.E.; Makris, G.C.; Matthaiou, D.K.; Rafailidis, P.I. Statins for infection and sepsis: a systematic review of the clinical evidence. J. Antimicrob. Chemother., 2008, 61(4), 774-785.
[http://dx.doi.org/10.1093/jac/dkn019] [PMID: 18263570]
[61]
Nseir, W.; Diab, H.; Mahamid, M.; Abu-Elheja, O.; Samara, M.; Abid, A.; Mograbi, J. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment. Pharmacol. Ther., 2012, 36(3), 231-238.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05161.x] [PMID: 22646167]
[62]
Dobesh, P.P.; Klepser, D.G.; McGuire, T.R.; Morgan, C.W.; Olsen, K.M. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy, 2009, 29(6), 621-630.
[http://dx.doi.org/10.1592/phco.29.6.621] [PMID: 19476415]
[63]
Liappis, A.P.; Kan, V.L.; Rochester, C.G.; Simon, G.L. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis., 2001, 33(8), 1352-1357.
[http://dx.doi.org/10.1086/323334] [PMID: 11565076]
[64]
Bergman, P.; Charlotte, L.; Katrin, P.; Anton, P.; Staffan, N.; Birgitta, HN.; Jan, A.; Linda, BB. Studies on the antibacterial effects of statins-in vitro and in vivo., 2011.
[http://dx.doi.org/10.1371/journal.pone.0024394]
[65]
Welsh, A.M.; Kruger, P.; Faoagali, J. Antimicrobial action of atorvastatin and rosuvastatin. Pathology, 2009, 41(7), 689-691.
[http://dx.doi.org/10.3109/00313020903305860] [PMID: 20001351]
[66]
Thangamani, S.; Mohammad, H.; Abushahba, M.F.; Hamed, M.I.; Sobreira, T.J.; Hedrick, V.E.; Paul, L.N.; Seleem, M.N. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci. Rep., 2015, 5, 16407.
[http://dx.doi.org/10.1038/srep16407] [PMID: 26553420]
[67]
Hennessy, E.; Mooij, M.J.; Legendre, C.; Reen, F.J.; O’Callaghan, J.; Adams, C.; O’Gara, F. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J. Antibiot. (Tokyo), 2013, 66(2), 99-101.
[http://dx.doi.org/10.1038/ja.2012.95] [PMID: 23149514]
[68]
Wang, C.C.; Yang, P.W.; Yang, S.F.; Hsieh, K.P.; Tseng, S.P.; Lin, Y.C. Topical simvastatin promotes healing of Staphylococcus aureus-contaminated cutaneous wounds. Int. Wound J., 2016, 13(6), 1150-1157.
[http://dx.doi.org/10.1111/iwj.12431] [PMID: 25752328]
[69]
Hackam, D.G.; Mamdani, M.; Li, P.; Redelmeier, D.A. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet, 2006, 367(9508), 413-418.
[http://dx.doi.org/10.1016/S0140-6736(06)68041-0] [PMID: 16458766]
[70]
Martin, C.P.; Talbert, R.L.; Burgess, D.S.; Peters, J.I. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy, 2007, 27(1), 20-26.
[http://dx.doi.org/10.1592/phco.27.1.20] [PMID: 17192158]
[71]
Tleyjeh, I.M.; Kashour, T.; Hakim, F.A.; Zimmerman, V.A.; Erwin, P.J.; Sutton, A.J.; Ibrahim, T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch. Intern. Med., 2009, 169(18), 1658-1667.
[http://dx.doi.org/10.1001/archinternmed.2009.286] [PMID: 19822822]
[72]
Schlienger, R.G.; Fedson, D.S.; Jick, S.S.; Jick, H.; Meier, C.R. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy, 2007, 27(3), 325-332.
[http://dx.doi.org/10.1592/phco.27.3.325] [PMID: 17316144]
[73]
Majumdar, S.R.; McAlister, F.A.; Eurich, D.T.; Padwal, R.S.; Marrie, T.J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ, 2006, 333(7576), 999-1006.
[http://dx.doi.org/10.1136/bmj.38992.565972.7C] [PMID: 17060337]
[74]
Ridker, P.M.; MacFadyen, J.; Libby, P.; Glynn, R.J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol., 2010, 106(2), 204-209.
[http://dx.doi.org/10.1016/j.amjcard.2010.03.018] [PMID: 20599004]
[75]
Hsia, J.; MacFadyen, J.G.; Monyak, J.; Ridker, P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). J. Am. Coll. Cardiol., 2011, 57(16), 1666-1675.
[http://dx.doi.org/10.1016/j.jacc.2010.09.082] [PMID: 21492764]
[76]
Odds, F.C.; Brown, A.J.; Gow, N.A. Antifungal agents: mechanisms of action. Trends Microbiol., 2003, 11(6), 272-279.
[http://dx.doi.org/10.1016/S0966-842X(03)00117-3] [PMID: 12823944]
[77]
Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: human fungal infections. Sci. Transl. Med., 2012, 4(165)165rv13
[http://dx.doi.org/10.1126/scitranslmed.3004404] [PMID: 23253612]
[78]
Aronson, J.K. Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions; Elsevier, 2005, Vol. 28, .
[79]
Chamilos, G.; Lewis, R.E.; Kontoyiannis, D.P. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob. Agents Chemother., 2006, 50(1), 96-103.
[http://dx.doi.org/10.1128/AAC.50.1.96-103.2006] [PMID: 16377673]
[80]
Menezes, E.A.; Vasconcelos Júnior, A.A.; Silva, C.L.; Plutarco, F.X. Cunha, Mda.C.; Cunha, F.A. In vitro synergism of simvastatin and fluconazole against Candida species. Rev. Inst. Med. Trop. São Paulo, 2012, 54(4), 197-199.
[http://dx.doi.org/10.1590/S0036-46652012000400003] [PMID: 22850990]
[81]
Natesan, S.K.; Chandrasekar, P.H.; Alangaden, G.J.; Manavathu, E.K. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn. Microbiol. Infect. Dis., 2008, 60(4), 369-373.
[http://dx.doi.org/10.1016/j.diagmicrobio.2007.10.015] [PMID: 18061388]
[82]
Spanakis, E.K.; Kourkoumpetis, T.K.; Livanis, G.; Peleg, A.Y.; Mylonakis, E. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin. Proc., 2010, 85(12), 1073-1079.
[http://dx.doi.org/10.4065/mcp.2010.0447] [PMID: 21123633]
[83]
Magulick, J.P.; Frei, C.R.; Ali, S.K.; Mortensen, E.M.; Pugh, M.J.; Oramasionwu, C.U.; Daniels, K.R.; Mansi, I.A. The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. Am. J. Med. Sci., 2014, 347(3), 211-216.
[http://dx.doi.org/10.1097/MAJ.0b013e31828318e2] [PMID: 23426088]
[84]
Forrest, G.N.; Kopack, A.M.; Perencevich, E.N. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect. Dis., 2010, 10, 152-158.
[http://dx.doi.org/10.1186/1471-2334-10-152] [PMID: 20525374]
[85]
Grellier, P.; Valentin, A.; Millerioux, V.; Schrevel, J.; Rigomier, D. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes. Antimicrob. Agents Chemother., 1994, 38(5), 1144-1148.
[http://dx.doi.org/10.1128/AAC.38.5.1144] [PMID: 8067753]
[86]
Pradines, B.; Torrentino-Madamet, M.; Fontaine, A.; Henry, M.; Baret, E.; Mosnier, J.; Briolant, S.; Fusai, T.; Rogier, C. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob. Agents Chemother., 2007, 51(7), 2654-2655.
[http://dx.doi.org/10.1128/AAC.01330-06] [PMID: 17502414]
[87]
Reis, P.A.; Estato, V.; da Silva, T.I.; d’Avila, J.C.; Siqueira, L.D.; Assis, E.F.; Bozza, P.T.; Bozza, F.A.; Tibiriça, E.V.; Zimmerman, G.A.; Castro-Faria-Neto, H.C. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog., 2012, 8(12)e1003099
[http://dx.doi.org/10.1371/journal.ppat.1003099] [PMID: 23300448]
[88]
Melo, L.; Caldas, I.S.; Azevedo, M.A.; Gonçalves, K.R.; da Silva do Nascimento, A.F.; Figueiredo, V.P.; de Figueiredo Diniz, L.; de Lima, W.G.; Torres, R.M.; Bahia, M.T.; Talvani, A. Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs. Am. J. Trop. Med. Hyg., 2011, 84(2), 325-331.
[http://dx.doi.org/10.4269/ajtmh.2011.10-0451] [PMID: 21292909]
[89]
Kumar, G.A.; Roy, S.; Jafurulla, M.; Mandal, C.; Chattopadhyay, A. Statin-induced chronic cholesterol depletion inhibits Leishmania donovani infection: Relevance of optimum host membrane cholesterol. Biochim. Biophys. Acta, 2016, 1858(9), 2088-2096.
[http://dx.doi.org/10.1016/j.bbamem.2016.06.010] [PMID: 27319380]
[90]
V.; CostinTeodor, S.; Liliana, S.; Ion, R, Statins in the Treatment of Hepatitis C. Hepatitis Month. 2012, pp. 369-371.
[91]
Delang, L.; Paeshuyse, J.; Vliegen, I.; Leyssen, P.; Obeid, S.; Durantel, D.; Zoulim, F.; Op de Beeck, A.; Neyts, J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology, 2009, 50(1), 6-16.
[http://dx.doi.org/10.1002/hep.22916] [PMID: 19437494]
[92]
Mehrbod, P.; Omar, A.R.; Hair-Bejo, M.; Haghani, A.; Ideris, A. Mechanisms of action and efficacy of statins against influenza. BioMed Res. Int., 2014.2014872370
[http://dx.doi.org/10.1155/2014/872370] [PMID: 25478576]
[93]
Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol., 2005, 19(1), 117-125.
[http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x] [PMID: 15660968]
[94]
Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 1999, 84(3), 413-428.
[http://dx.doi.org/10.1016/S0163-7258(99)00045-5] [PMID: 10665838]
[95]
Jacobson, T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol., 2004, 94(9), 1140-1146.
[http://dx.doi.org/10.1016/j.amjcard.2004.07.080] [PMID: 15518608]
[96]
Czub, J.; Baginski, M. Comparative molecular dynamics study of lipid membranes containing cholesterol and ergosterol. Biophys. J., 2006, 90(7), 2368-2382.
[http://dx.doi.org/10.1529/biophysj.105.072801] [PMID: 16399829]
[97]
Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292(5519), 1160-1164.
[http://dx.doi.org/10.1126/science.1059344] [PMID: 11349148]
[98]
Farmer, A.R.; Murray, C.K.; Mende, K.; Akers, K.S.; Zera, W.C.; Beckius, M.L.; Yun, H.C. Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods. J. Basic Microbiol., 2013, 53(4), 336-339.
[http://dx.doi.org/10.1002/jobm.201100614] [PMID: 22736455]
[99]
Chow, O.A.; von Köckritz-Blickwede, M.; Bright, A.T.; Hensler, M.E.; Zinkernagel, A.S.; Cogen, A.L.; Gallo, R.L.; Monestier, M.; Wang, Y.; Glass, C.K.; Nizet, V. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe, 2010, 8(5), 445-454.
[http://dx.doi.org/10.1016/j.chom.2010.10.005] [PMID: 21075355]
[100]
Martín-Navarro, C.M.; López-Arencibia, A.; Sifaoui, I.; Reyes-Batlle, M.; Valladares, B.; Martínez-Carretero, E.; Piñero, J.E.; Maciver, S.K.; Lorenzo-Morales, J. Statins and voriconazole induce programmed cell death in Acanthamoeba castellanii. Antimicrob. Agents Chemother., 2015, 59(5), 2817-2824.
[http://dx.doi.org/10.1128/AAC.00066-15] [PMID: 25733513]
[101]
Liu, G.; Vellucci, V.F.; Kyc, S.; Hostetter, M.K. Simvastatin inhibits Candida albicans biofilm in vitro. Pediatr. Res., 2009, 66(6), 600-604.
[http://dx.doi.org/10.1203/PDR.0b013e3181bd5bf8] [PMID: 19707174]
[102]
Rahal, E.A.; Constantin, W.N.; Zeidan, N.; Abdelnoor, A.M. Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice. Front. Microbiol., 2015, 6, 1474-1781.
[http://dx.doi.org/10.3389/fmicb.2015.01474] [PMID: 26732740]
[103]
Pirat, A.; Zeyneloglu, P.; Aldemir, D.; Yücel, M.; Ozen, O.; Candan, S.; Arslan, G. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth. Analg., 2006, 102(1), 225-232.
[http://dx.doi.org/10.1213/01.ane.0000189554.41095.98] [PMID: 16368834]
[104]
Merx, M.W.; Liehn, E.A.; Graf, J.; van de Sandt, A.; Schaltenbrand, M.; Schrader, J.; Hanrath, P.; Weber, C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation, 2005, 112(1), 117-124.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.502195] [PMID: 15998696]
[105]
Parihar, S.P.; Hartley, M.A.; Hurdayal, R.; Guler, R.; Brombacher, F. Topical simvastatin as host-directed therapy against severity of cutaneous leishmaniasis in mice. Sci. Rep., 2016, 6, 33458.
[http://dx.doi.org/10.1038/srep33458] [PMID: 27632901]
[106]
Chalmers, J.D.; Singanayagam, A.; Murray, M.P.; Hill, A.T. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am. J. Med., 2008, 121(11), 1002-1007.e1.
[http://dx.doi.org/10.1016/j.amjmed.2008.06.030] [PMID: 18954848]
[107]
Truwit, J.D.; Bernard, G.R.; Steingrub, J.; Matthay, M.A.; Liu, K.D.; Albertson, T.E.; Brower, R.G.; Shanholtz, C.; Rock, P.; Douglas, I.S.; deBoisblanc, B.P.; Hough, C.L.; Hite, R.D.; Thompson, B.T. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N. Engl. J. Med., 2014, 370(23), 2191-2200.
[http://dx.doi.org/10.1056/NEJMoa1401520] [PMID: 24835849]
[108]
Thomas, G.; Hraiech, S.; Loundou, A.; Truwit, J.; Kruger, P.; Mcauley, D.F.; Papazian, L.; Roch, A. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol., 2015, 81(8), 921-930.
[PMID: 25690048]
[109]
Hennessy, E.; Adams, C.; Reen, F.J.; O’Gara, F. Is there potential for repurposing statins as novel antimicrobials? Antimicrob. Agents Chemother., 2016, 60(9), 5111-5121.
[http://dx.doi.org/10.1128/AAC.00192-16] [PMID: 27324773]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [224 - 237]
Pages: 14
DOI: 10.2174/1871526518666180806123230
Price: $58

Article Metrics

PDF: 30